# Efficacy and Safety of Intravenous Neridronic Acid in CRPS

> **NCT03530345** · PHASE3 · TERMINATED · sponsor: **Grünenthal GmbH** · enrollment: 182 (actual)

## Conditions studied

- Complex Regional Pain Syndrome (CRPS)

## Interventions

- **DRUG:** Neridronic acid 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03530345
- **Lead sponsor:** Grünenthal GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-30
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 182 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03530345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03530345, "Efficacy and Safety of Intravenous Neridronic Acid in CRPS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03530345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*